- Home
- TNON vs THAR Comparison
TNON vs THAR Comparison
Compare TNON & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- THAR
- Stock Information
- Founded
- TNON 2012
- THAR 2017
- Country
- TNON United States
- THAR United States
- Employees
- TNON N/A
- THAR N/A
- Industry
- TNON Medical Specialities
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- THAR Health Care
- Exchange
- TNON Nasdaq
- THAR Nasdaq
- Market Cap
- TNON 4.8M
- THAR 4.0M
- IPO Year
- TNON 2022
- THAR 2022
- Fundamental
- Price
- TNON $1.39
- THAR $1.90
- Analyst Decision
- TNON Strong Buy
- THAR Strong Buy
- Analyst Count
- TNON 2
- THAR 1
- Target Price
- TNON $16.00
- THAR $17.00
- AVG Volume (30 Days)
- TNON 95.9K
- THAR 20.9K
- Earning Date
- TNON 03-11-2025
- THAR 11-07-2024
- Dividend Yield
- TNON N/A
- THAR N/A
- EPS Growth
- TNON N/A
- THAR N/A
- EPS
- TNON N/A
- THAR N/A
- Revenue
- TNON $3,315,000.00
- THAR N/A
- Revenue This Year
- TNON $29.03
- THAR N/A
- Revenue Next Year
- TNON $100.29
- THAR N/A
- P/E Ratio
- TNON N/A
- THAR N/A
- Revenue Growth
- TNON 38.30
- THAR N/A
- 52 Week Low
- TNON $1.35
- THAR $1.84
- 52 Week High
- TNON $15.79
- THAR $7.46
- Technical
- Relative Strength Index (RSI)
- TNON 32.21
- THAR 43.41
- Support Level
- TNON $1.35
- THAR $1.86
- Resistance Level
- TNON $1.59
- THAR $1.95
- Average True Range (ATR)
- TNON 0.11
- THAR 0.07
- MACD
- TNON 0.01
- THAR -0.00
- Stochastic Oscillator
- TNON 14.81
- THAR 16.33
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.